New Zealand's PHARMAC Picks Up Douglas To Dump Novartis; Funds Dr. Reddy's Risperidone, Schering-Plough's Avanza
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Beginning Nov. 1, Schering-Plough's antidepressant Avanza (mirtazapine) will be listed on New Zealand's Pharmaceutical Schedule for second-line treatment of severe depression, the Pharmaceutical Management Agency reported